fosun pharma recognized as one of the first national intellectual property advantage enterprises
on november 27, 2013, state intellectual property office of p.r.c published the notice of recognition of the first national intellectual property model enterprises and advantage enterprises on its website, which recognized 127 enterprises as the first national intellectual property model enterprises and 771 enterprises as the first national intellectual property advantage enterprises. fosun pharma is one of them.
fosun pharma is a leading listed pharmaceutical company in china (stock code: 600196-sh, 02196-hk). focusing on innovation, research and development, fosun pharma is a national technology center, having its international r&d team at shanghai, chongqing and usa. in recent years, fosun pharma keeps increasing its r&d investment, equal to 5-10% of the total pharmaceutical sales, to support innovation in research. meanwhile, fosun pharma adopted a patent strategy focusing on new products with intellectual property. in its key business of pharmaceuticals, fosun pharma has its exclusive core patent technology and patent team focusing on searching and development of blockbuster drugs through various ways such as r&d, new model of industry-academy-research alliance and licensing. fosun pharma and its affiliated companies were known to have applied for more than 60 patents in each year on average in recent years, and have been actively looking for patent protection in target markets (such as europe and usa). fosun pharma was also involving actively in the patent licensing out business. one of the examples is that a new compound fotagliptin benzoate for the treatment of type ii diabetes developed by fochon pharma a subsidiary of fosun pharma was licensed out recently; and another example is that guilin pharma a subsidiary of fosun pharma has been involved in making the who standard for artemisinin-based antimalarials and has entered the global markets successfully. fosun pharma was also recognized by state intellectual property office as one of the second advanced units of the national enterprises patent pilot projects and one of the first shanghai intellectual property model enterprises.
the recognition of fosun pharma as one of the first national intellectual property advantage enterprises shows its intellectual property achievement in recent years. it will help the company’s further development of r&d as well as the intellectual property protection, and finally improve its core competency and brand image.